56. Behcet disease Clinical trials / Disease details
Clinical trials : 76 / Drugs : 110 - (DrugBank : 32) / Drug target genes : 36 - Drug target pathways : 116
Showing 1 to 10 of 76 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04528082 (ClinicalTrials.gov) | September 9, 2021 | 24/8/2020 | Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN) A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed ... | Behçet Disease | Drug: Apremilast;Drug: Placebo | Amgen | NULL | Recruiting | 2 Years | 17 Years | All | 60 | Phase 3 | France;Greece;Israel;Italy;Spain;Switzerland;United Kingdom |
| 2 | EUCTR2019-002787-27-IT (EUCTR) | 24/05/2021 | 07/06/2021 | Apremilast study in children with active oral ulcers associated with Behçet's Disease | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled,Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN) - BEAN A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled,Parallel Group Study, Followed ... | Subjects with active Behçet's Disease MedDRA version: 21.1;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Subjects with active Behçet's Disease MedDRA version: 21.1;Level: LLT;Classification code 10004212;T ... | Trade Name: OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG Product Name: Apremilast Product Code: [AMG407] INN or Proposed INN: Apremilast Trade Name: OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG Product Name: Apremilast Product Code: [AMG407] INN or Proposed INN: Apremilast Trade Name: OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG Product Name: Apremilast Product Code: [AMG 407] INN or Proposed INN: Apremilast Product Name: Apremilast Product Code: [AMG407] INN or Proposed INN: Apremilast Trade Name: OTEZLA- 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) ... | AMGEN INC. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 3 | France;Greece;Israel;Netherlands;Switzerland;Italy | ||
| 3 | EUCTR2019-002787-27-GR (EUCTR) | 20/05/2021 | 07/05/2021 | Apremilast study in children with active oral ulcers associated with Behçet’s Disease | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet’s Disease (BEAN) A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed ... | Subjects with active Behçet’s Disease MedDRA version: 21.1;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Subjects with active Behçet’s Disease MedDRA version: 21.1;Level: LLT;Classification code 10004212;T ... | Trade Name: Otezla Product Name: Apremilast 10 mg Product Code: AMG-407 INN or Proposed INN: Apremilast Trade Name: Otezla Product Name: Apremilast 20 mg Product Code: AMG-407 INN or Proposed INN: Apremilast Trade Name: Otezla Product Name: Apremilast 30 mg Product Code: AMG-407 INN or Proposed INN: Apremilast Product Name: Apremilast Product Code: AMG407 INN or Proposed INN: Apremilast Trade Name: Otezla Product Name: Apremilast10 mg Product Code: AMG-407 INN or Proposed INN: Apremilast T ... | Amgen Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 3 | France;Greece;Israel;Netherlands;Switzerland | ||
| 4 | ChiCTR2100045463 | 2021-05-01 | 2021-04-15 | Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interventional, open-label, single-arm study Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interv ... | Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interventional, open-label, single-arm study Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interv ... | intestinal Beh?et's disease | One-armed intervention group:adalimumab; | The First Affiliated Hospital, College of Medicine, Zhejiang University | NULL | Recruiting | 18 | 70 | Both | One-armed intervention group:30; | Phase 4 | China |
| 5 | ChiCTR2100044593 | 2021-03-15 | 2021-03-24 | Clinical study of endoscopic treatment for Patients with intestinal Behcet's disease having poor response to conventional treatment Clinical study of endoscopic treatment for Patients with intestinal Behcet's diseasehaving poor resp ... | Clinical study of endoscopic treatment for Patients with intestinal Behcet's disease having poor response to conventional treatment Clinical study of endoscopic treatment for Patients with intestinal Behcet's diseasehaving poor resp ... | intestinal Behcet's disease | Single group:Endoscopic injection of triamcinolone acetonide; | The First Affiliated Hospital of Sun Yat-Sen University | ,NULL | Recruiting | 16 | 70 | Both | Single group:30; | China | |
| 6 | ChiCTR2000037172 | 2021-01-01 | 2020-08-27 | Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatment of Mucocutaneous Behcet's Disease Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatme ... | Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatment of Mucocutaneous Behcet's Disease Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatme ... | Behcet's Disease | experimental group:Shen's Qinlian Soil Fuling Granules + Thalidomide Tablets;control group:placebo + Thalidomide Tablets ; experimental group:Shen's Qinlian Soil Fuling Granules + ThalidomideTablets;control group:placebo + ... | Shanghai Traditional Chinese Medicine Hospital | NULL | Pending | 16 | 70 | Both | experimental group:60;control group:60; | China | |
| 7 | NCT04609397 (ClinicalTrials.gov) | November 30, 2020 | 19/10/2020 | A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease | A Phase ? Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease | Behçet Disease | Drug: Hemay005;Other: Placebo | Tianjin Hemay Pharmaceutical Co.,Ltd | NULL | Recruiting | 18 Years | 75 Years | All | 252 | Phase 2 | China |
| 8 | ChiCTR2000031637 | 2020-04-10 | 1990-01-01 | Behcet’s Uveitis Therapy (BUT) Study | Behcet’s Uveitis Therapy (BUT) Study | Uveitis in Behcet’s Disease | Arm A: Interferon Alpha-2a;Arm B:Adalimumab;Arm C:Cyclosporine; | The First Affiliated Hospital of Chongqing Medical University | NULL | Pending | Both | Arm A:90;Arm B:90;Arm C:90; | Phase 4 | China | ||
| 9 | NCT04218565 (ClinicalTrials.gov) | February 15, 2020 | 8/12/2019 | Golimumab for the Treatment of Refractory Behcet's Uveitis | Efficacy and Safety of Golimumab in the Treatment of Refractory Uveitis in Patients With Behcet's Disease Efficacy and Safety of Golimumab in the Treatment of Refractory Uveitis in Patients With Behcet's Di ... | Behcet Syndrome;Uveitis | Biological: Golimumab (GOL) | Wenjie Zheng | NULL | Recruiting | 18 Years | 65 Years | All | 9 | Phase 2 | China |
| 10 | NCT04186559 (ClinicalTrials.gov) | February 2020 | 2/12/2019 | Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers | Clinical Protocol to Evaluate Use of Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers | Behcet Syndrome;Behcet Disease | Drug: Topical Pentoxifylline Gel (Vehicle +PTX);Drug: Topical Placebo Gel (Vehicle) | Silk Road Therapies, Inc. | NULL | Not yet recruiting | 18 Years | N/A | All | 60 | Phase 2 | United States |